ATE386537T1 - Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette - Google Patents

Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette

Info

Publication number
ATE386537T1
ATE386537T1 AT95924766T AT95924766T ATE386537T1 AT E386537 T1 ATE386537 T1 AT E386537T1 AT 95924766 T AT95924766 T AT 95924766T AT 95924766 T AT95924766 T AT 95924766T AT E386537 T1 ATE386537 T1 AT E386537T1
Authority
AT
Austria
Prior art keywords
gamma chain
receptor
cytokine receptor
cell
interleukin
Prior art date
Application number
AT95924766T
Other languages
English (en)
Inventor
Vassiliki Boussiotis
Lee Nadler
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE386537T1 publication Critical patent/ATE386537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT95924766T 1994-07-01 1995-06-30 Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette ATE386537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/270,152 US6576236B1 (en) 1994-07-01 1994-07-01 Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain

Publications (1)

Publication Number Publication Date
ATE386537T1 true ATE386537T1 (de) 2008-03-15

Family

ID=23030131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95924766T ATE386537T1 (de) 1994-07-01 1995-06-30 Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette

Country Status (10)

Country Link
US (2) US6576236B1 (de)
EP (2) EP0768890B1 (de)
JP (2) JPH10502372A (de)
AT (1) ATE386537T1 (de)
AU (1) AU2915295A (de)
CA (1) CA2194239A1 (de)
DE (1) DE69535713T2 (de)
DK (1) DK0768890T3 (de)
ES (1) ES2299174T3 (de)
WO (1) WO1996001122A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362192B2 (ja) * 1994-12-06 2003-01-07 味の素株式会社 検査方法及び検査薬
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
CA2220226C (en) * 1995-05-04 2008-10-21 Carl H. June Improved methods for transfecting t cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
DE59605711D1 (de) * 1995-10-11 2000-09-14 Arteva Tech Sarl Schwerentflammbare Sicherheitsgurte enthaltend phosphor-modifizierte Polyesterfasern
FR2745185B1 (fr) 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
ATE476496T1 (de) * 1996-03-04 2010-08-15 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
JP2001511649A (ja) * 1997-02-07 2001-08-14 トーマス・ジェファーソン・ユニバーシティ サイトカインレセプターガンマ鎖のペプチド模倣物
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
WO2001057534A2 (en) * 2000-02-04 2001-08-09 Bioseek Compositions and methods for reducing autoimmunity
WO2002079499A1 (en) * 2001-04-02 2002-10-10 Wyeth Pd-1, a receptor for b7-4, and uses therefor
CA2526586C (en) 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
CN101573139A (zh) * 2006-02-16 2009-11-04 纳森特生物制剂公司 在哺乳动物个体中改善免疫功能的方法以及预防或治疗疾病的方法
EP2680010A1 (de) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2-screening-assays sowie entsprechende verfahren und zusammensetzungen
HK1221260A1 (zh) * 2013-06-24 2017-05-26 Celgene Corporation 扩增t细胞的方法
WO2020160242A1 (en) 2019-02-01 2020-08-06 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0436597B1 (de) 1988-09-02 1997-04-02 Protein Engineering Corporation Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2003455C (en) 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DK0441917T3 (da) * 1989-07-25 1996-09-16 Oncogen Antiviralt kermesbær-protein - monoklonalt antistofkonjugater
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1992004044A1 (en) * 1990-09-06 1992-03-19 Schering Corporation Use of il-4 to treat solid tumors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (de) 1991-03-01 2009-08-12 Dyax Corporation Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
US5582826A (en) * 1993-04-21 1996-12-10 Ajinomoto Co., Inc. Monoclonal antibodies which bind the gamma chain of human interleukin-2 receptor
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain

Also Published As

Publication number Publication date
EP0768890B1 (de) 2008-02-20
ES2299174T3 (es) 2008-05-16
WO1996001122A1 (en) 1996-01-18
EP1958966A2 (de) 2008-08-20
DE69535713D1 (de) 2008-04-03
US6576236B1 (en) 2003-06-10
AU2915295A (en) 1996-01-25
DE69535713T2 (de) 2009-03-19
US20040037808A1 (en) 2004-02-26
EP0768890A1 (de) 1997-04-23
JPH10502372A (ja) 1998-03-03
CA2194239A1 (en) 1996-01-18
DK0768890T3 (da) 2008-06-09
JP2007112815A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
ATE386537T1 (de) Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette
ATE201236T1 (de) Zur ortsspezifischen rekomination fähige agrobakterium stämme
DE3577564D1 (de) Polymere zur verwendung als hilfsmittel in der filtrationskontrolle fuer bohrfluessigkeiten.
DE3750800D1 (de) Verfahren zur Erzeugung von Anzeigen mit veränderlichen Skalen.
ATE266671T1 (de) Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen
DK0414475T3 (da) Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier
DE3671640D1 (de) Kationische emulsionen von bitumen-polymerartigen bituminoesen bindemitteln und kationisches emulgiersystem, unter anderem verwendbar zur erhaltung derselben.
ATA901987A (de) Vorrichtung zur erzeugung von gas aus festen brennstoffen
DE59001452D1 (de) Verfahren zur optimierung der verbrennung von kraftstoffen bei minimaler co-emission und vorrichtung zur durchfuehrung des verfahrens.
NO854710L (no) Fremgangsmåte for kontroll og styring av injeksjonssonens utstrekning ved jetinjisering av herdbart bindemiddel i jordarter, samt anordning for gjennomføring av fremgangsmåten.
DE3766500D1 (de) Verfahren zur dehalogenierung von halogenierten kohlenwasserstoffen.
DE69314024D1 (de) NEUE GABAa-REZEPTORSUBTYPEN UND VERFAHREN ZUM SCREENING VON ARZNEIMITTELVERBINDUNGEN UNTER VERWENDUNG VON GABAa-REZEPTORSUBTYPEN BINDENDE IMIDAZOCHINOXALINE UND PYRROLOPYRIMIDINE
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
DE3485319D1 (de) Rekombinante dns, diese rekombinante dns enthaltende bakterien, und verfahren zur herstellung von l-threonin oder l-isoleucin unter verwendung dieser bakterien.
ATA171787A (de) Heizanlage zum verbrennen von festen brennstoffen
ATE173295T1 (de) Ecdysteroid-abhängige gen regulierung in säugetier-zellen
DE3672797D1 (de) Armierungseisenhalter zur verwendung bei anschlussbetonierungen.
ATE112312T1 (de) Lösliche verkürzte interferon-gamma rezeptoren.
DE3480928D1 (de) 5-substituierte 2-pyrimidinon-nukleoside und verfahren zu ihrer verwendung.
ATE45746T1 (de) Substituierte o-acyl-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung.
DE3851493D1 (de) Methode und anlage zur erzeugung von lichtstrahlung aus freiem positronium.
ATE153997T1 (de) Entfärbung von alkylierten diarylaminen
BR9604947A (pt) Genes que codificam polipept¡deos (lsirf) fatores reguladores de interferon linfoc¡tico
AT375954B (de) Verfahren zur herstellung von selbstvernetzenden, kathodisch abscheidbaren etl-bindemitteln auf basis modifizierter phenol-novolake
DE3768433D1 (de) Durch protonierung mit saeure wasserverduennbare bindemittel.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties